Dr. Elizabeth Buck Ph.D. serves as Executive Vice President - Discovery and Translational Services of the Company. Prior to joining us, from September 2013 to December 2014, Dr. Buck served as Chief Scientific Officer for Therapeutics at MetaStat, Inc., a precision medicine biotechnology company. Previously, from 2005 to 2013, Dr. Buck was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, Inc., a pharmaceutical company acquired by Astellas Pharma Inc., where she led discovery and translational research to advance a series of oncology programs to clinical development. In this role, Dr. Buck managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to IND. Her expertise and productivity are evidenced by more than 40 peer reviewed publications and patents. Dr. Buck received her undergraduate degree in Physics from the University of New Hampshire, her Ph.D. in Cellular and Molecular Biology from New York University/Mount Sinai School of Medicine, and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals, Inc., a publicly traded biopharmaceutical company.
Elizabeth Buck is 45, he's been the Executive Vice President - Discovery and Translational Services of Black Diamond Therapeutics Inc since 2017. There are 14 older and 4 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
Elizabeth's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah a Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: